But since its 2011 approval by the US Food and Drug Administration (FDA) doubts have grown about its apparent advantage over cheaper, off patent P2Y12 inhibitors like clopidogrel and prasugrel. While AstraZeneca, ticagrelor's manufacturer, reported superior efficacy to clopidogrel in the phase 3 ...